OOOzgur Oktem

Ozgur Oktem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ozgur Oktem has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety, Feasibility and Indications of Transabdominal Oocyte Pick-Up: Initial Experience

    by Volkan Turan, Ozgur Oktem

    Although the transvaginal route is the preferred method for the oocyte retrieval procedure, the transabdominal (TA) route may be preferred in certain conditions. In this opinion we presented our experience with TA oocyte pick-up in 101 patients across several different indications and assessed the safety of the procedure.

  • Open Access

    The Impact of Conventional Chemotherapy Regimens and Targeted Drugs on Ovarian Function in Breast Cancer Patients

    by Seyma Haskoylu, Sevval Berfin Sahin, Alara Altıntas, Sule Yildiz, Gamze Bildik, Can Benlioglu, Volkan Turan, Samuel Kim, Ozgur Oktem

    Breast cancer is the most common malignancy among women, affecting nearly 1.5 million individuals worldwide every year. While survival rates improve, many reproductive-age survivors confront significant long-term consequences, particularly diminished ovarian reserve, infertility, and premature ovarian insufficiency due to the gonadotoxic effects of chemotherapy. Postponement of pregnancy for five years or more after treatment exacerbates the decline in fertility due to ongoing ovarian aging and depletion of residual ovarian reserve. Women carrying BRCA1/2 mutations may already exhibit reduced ovarian reserve and are more vulnerable to gonadal damage, possibly due to impaired DNA repair mechanisms associated with these mutations. The contribution of other breast cancer susceptibility genes (e.g., ATM, CHEK2, PALB2, BARD1, RAD51C, RAD51D, and TP53) to chemotherapy-induced gonadotoxicity remains unclear. Although animal data shows depletion of primordial follicle pool and granulosa cells dysfunction, the ovarian effects of the poly(ADP-ribose) polymerase (PARP) inhibitors in women with and without BRCA mutation are not clear. Immune-check point inhibitors (ICIs) causes immune-mediated destruction of the primordial follicle pool and reduction in ovarian reserve. Cyclin dependent kinase inhibitors appear to be less toxic than ICIs. In this narrative review of the current literature we aimed to provide a comprehensive overview of the molecular mechanisms underlying ovarian toxicity associated with conventional chemotherapy and targeted therapies in breast cancer treatment.

  • Endometriomas are heterogeneous for functional FSH receptor expression and steroidogenic function

    by Can Benlioglu, Yashar Esmaeilian, Sevgi Yusufoglu, Hesam Ghafouri Kalajahi, Batuhan Altay, Seda Ates, Serdar Aydin, Uzeyir Kalkan, Pinar Bulutay, Ceyda Acilan, et al.

    We investigated whether ovarian endometriomas uniformly express functional FSH receptors (FSHR) and respond to FSH by activating transcriptional programs that drive aromatase and steroid hormone production. Endometrioma cyst capsules were obtained from 18 patients undergoing surgery between January 2020 and December 2024. FSHR and steroidogenic pathway components were evaluated using qRT-PCR, quantitative immunoblotting, and immunohistochemistry. To assess FSH responsiveness, explant cultures were exposed to FSH, and the expression of five FSH-responsive CYP19A1 (aromatase) transcript variants (alternative exons I.1, I.2; I.3; I.4, and promoter II) was quantified; estradiol (E2) and progesterone (P4) were measured in spent culture media. Human granulosa cells served as positive controls for steroidogenesis/FSHR, and the eutopic endometrium served as the estrogen receptor profiling control. FSHR transcripts were detected in all endometriomas and were several-fold higher than in granulosa-cell controls; however, FSHR protein abundance was lower and highly variable, and transcript–protein levels were discordant, indicating marked mRNA–protein uncoupling. FSH did not elicit a uniform aromatase response: only selected transcript variants were upregulated in a lesion-dependent manner, and induction of one or more CYP19A1 variants did not consistently translate into increased E2 output. Moreover, E2 production did not correlate with aromatase protein abundance. Protein expression of StAR and downstream steroidogenic enzymes (CYP11A1/SCC, 3β-HSD, and 17β-HSD) also showed substantial inter-patient heterogeneity. Collectively, ovarian endometriomas exhibit pronounced heterogeneity in functional FSHR expression, steroidogenic enzyme profiles, FSH-driven aromatase transcript programs, and hormone output, which may contribute to variable lesion behavior during ovarian stimulation; findings were derived from unilateral endometriomas and may not generalize to multifocal disease or other lesion types.

  • Clinical and molecular features of ovarian stimulation in peripubertal girls with mosaic Turner’s syndrome

    by Ozgur Oktem, Hesam Ghafouri Kalajahi, Yashar Esmaeilian, Can Benlioglu, Francesko Hela, Sevgi Yusufoglu, Uzeyir Kalkan, Volkan Turan, Baris Ata

    STUDY QUESTION: Do peripubertal girls with mosaic Turner’s syndrome (TS) respond to ovarian stimulation (OS) for oocyte freezing as adult women with normal ovarian reserve? SUMMARY ANSWER: Clinical and molecular reproductive/endocrine features of OS in these patients are similar to those of adult females. WHAT IS KNOWN ALREADY: OS for oocyte freezing is quite a new concept in peripubertal and young adolescent girls with TS because ovarian tissue cryopreservation (OTC) does not have proven efficacy, likely due to already diminished ovarian reserve and accelerated follicle atresia. No data are available in the literature regarding the molecular IVF characteristics of these cycles in this group of patients. We aimed to address this issue in the current study by analyzing gonadotropin receptor expression, response to gonadotropins, and steroidogenic function at the molecular level in four peripubertal patients aged 9, 12, 13, and 15 in comparison to control adult females with normal ovarian reserve undergoing OS for male factor infertility. STUDY DESIGN, SIZE, DURATION: This is a clinical and research study that simultaneously analyzes the clinical and molecular characteristics of OS in peripubertal young girls with TS between 2021 and 2023 at a university hospital and translational research center. PARTICIPANTS/MATERIALS, SETTING, METHODS: All participants underwent OS using a progestin-primed protocol with recombinant forms of FSH and LH, and final maturation was induced with recombinant hCG. Control patients who had normal ovarian reserve and underwent OS for male factor infertility were randomly recruited during the study period to simultaneously compare and analyze the clinical and molecular OS characteristics of the peripubertal TS cases. Luteinized mural granulosa cells obtained during oocyte retrieval procedures were used for the experiments. Cell culture, quantitative real-time PCR, immunoblotting, confocal time-lapse live-cell imaging, and hormone assays were used. MAIN RESULTS AND THE ROLE OF CHANCE: All TS cases responded to gonadotropin stimulation. Nine mature oocytes were retrieved and vitrified in the 9-year-old prepubertal mosaic TS case after four cycles of OS with r-FSH (300 IU) and r-LH (150 IU)/day after a mean stimulation period of 9.72 ± 2.1 days. Eight mature oocytes were retrieved in the case aged 13 after three rounds of OS. The other cases, aged 12 and 15, underwent only one cycle of OS, and two mature oocytes from each were retrieved. The expression of FSH/LH receptors and steroidogenic enzymes, basal and gonadotropin-induced up-regulation in the expression of the steroidogenic enzymes, and estradiol and progesterone productions of the GCs of the TS patients were similar to those of adult control patients. Confocal immunofluorescence microscopy and live imaging revealed no differences in cholesterol uptake/trafficking or in staining patterns of the steroidogenic enzymes and their co-localization with mitochondria and cholesterol-laden lipid droplets. LIMITATIONS, REASONS FOR CAUTION: Findings were obtained from a limited number of mosaic TS patients. It is unclear if these findings are reproducible in non-mosaic peripubertal cases. Furthermore, no data are available yet regarding the post-thaw survival, fertilization, embryo development competency, euploidy status, and obstetrical outcomes of the vitrified oocytes of these patients. WIDER IMPLICATIONS OF THE FINDINGS: This study provides reassuring clinical and molecular evidence that OS for oocyte freezing can be an option in young girls with mosaic TS who are not ideal candidates for OTC due to diminished ovarian reserve. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the School of Medicine, the Graduate School of Health Sciences, and the Research Center for Translational Medicine (KUTTAM) at Koç University. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: Not applicable.


  • Role of Ovarian Stem Cells in Postnatal Oogenesis and Implications in Fertility Preservation

    by C. Benlioglu, V. Turan, Ozgur Oktem

    It is a long-held dogma in reproductive biology that females are born with a set nonrenewable number of oocytes in the ovary. While some animal studies challenged this dogma by demonstrating allegedly postnatal oogenesis and the presence of certain stem cell factor expression germ cell markers, their biological roles are yet to be defined. In this chapter, we revisited this issue revisit this dogma in light of most recent data. The chapter outlines the characteristics of these putative OSCs, including their morphological features, expression of germline markers (e.g., DDX4, DAZL), telomerase activity, and methods for their isolation and culture, acknowledging the ongoing debate and methodological controversies surrounding their identification, particularly the reliability of DDX4-based sorting. We critically evaluate the evidence for their capacity to differentiate into oocyte-like cells in vitro and in vivo, including experiments involving transplantation into animal models. Finally, the chapter explores the profound implications these OSCs hold for fertility preservation, especially for women facing premature ovarian insufficiency, age-related infertility, or gonadotoxic treatments. We discuss potential future applications, such as autologous OSC transplantation to restore ovarian function or in vitro generation of mature oocytes for fertilization. We highlight the significant technical and safety hurdles that must be overcome, including optimizing culture systems, ensuring genomic stability, and validating human functional competency. While the physiological role and definitive existence of functional OSCs in adult human ovaries remain contentious subjects requiring further rigorous investigation using advanced techniques like single-cell analysis and lineage tracing, the potential therapeutic promise continues to drive research in this exciting, albeit controversial, area of reproductive medicine.


  • Open Access

    Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system

    by Bahadır Köylü, Buğra Han Esen, Şevval Nur Bektaş, Laşin Özbek, Volkan Turan, Bülent Urman, Özgür Öktem, Fatih Selçukbiricik

    This study aims to investigate the adverse effects of immune checkpoint inhibitors (ICIs) on the female and male reproductive systems. In the FDA Adverse Event Reporting System (FAERS) database, adverse reactions under the “Reproductive system and breast disorders” category in the System Organ Classes were included, covering a period from January 1, 2015, to June 30, 2023. We identified 133,512 patients treated with ICIs. Immune checkpoint inhibitor-related reproductive adverse effects (irRAEs) were reported in 568 (0.43%) patients. Spermatogenesis abnormality (ROR025 = 7.91) had the highest signal strength associated with ICI use in males. Genital tract fistula was the only significant irRAE (ROR025 = 2.72) in females. PD-1 inhibitors pose greater risk than CTLA-4 inhibitors (OR = 1.65 [1.05–2.79], p = 0.045). Gynecologic cancers in females (OR = 3.77 [2.82–4.99], p < 0.0001) and urogenital cancers in males (OR = 1.56 [1.17–2.06], p = 0.0018) carried the highest risk compared to other cancers. Additional targeted drugs (OR = 2.32 [1.76–3.02], p < 0.0001), particularly lenvatinib (OR = 3.50 [2.48–4.94], p < 0.0001) and cabozantinib (OR = 3.71 [1.96–7.03], p < 0.0001) significantly increased the risk for females. Additional use of chemotherapy drugs was associated with a significant reduction in the risk for males (OR = 0.65 [0.42–0.96], p = 0.042) except for doxorubicin (OR = 2.58 [1.22–5.47], p = 0.013) and cyclophosphamide (OR = 2.36 [1.05–5.29], p = 0.038). This study demonstrates that ICIs could potentially lead to a wide range of adverse effects in the reproductive system in both males and females.


  • Exposure of antral follicles to medroxyprogesterone acetate during stimulation does not cause molecular perturbations in gonadotropin-responsiveness and steroidogenic function of granulosa cells in progestin-primed cycles

    by Ozgur Oktem, Yashar Esmaeilian, Ece İlTumur, Sevgi Yusufoglu, Deniz Uğurlu Çimen, Said Incir, Kayhan Yakin, Baris Ata, Bulent Urman

    STUDY QUESTION: Does medroxyprogesterone acetate (MPA) exposure in progestin-primed ovarian stimulation (PPOS) cycles cause molecular perturbations in the steroidogenic function and gonadotropin responsiveness of the granulosa cells? SUMMARY ANSWER: PPOS cycles are identical to traditional GnRH antagonist cycles not only for clinical IVF characteristics but also for gonadotropin receptor expression, response to gonadotropins, and steroidogenic function at the molecular level. WHAT IS KNOWN ALREADY: PPOS is increasingly used as an alternative to GnRH antagonists due to the inhibitory effect of progesterone on LH release by reducing GnRH pulsatility at the hypothalamic level. Although a growing body of evidence from clinical studies did not indicate significant differences between PPOS and antagonist protocols for IVF cycle characteristics and obstetrical outcomes, it is still unknown whether exposure of the antral follicle cohort to progesterone or its synthetic derivatives during ovarian stimulation causes any subtle molecular aberrations in terms of steroidogenesis and gonadotropin responsiveness. To address this issue, detailed comparative molecular analyses were conducted in the luteinized mural granulosa cells (GCs) obtained from normal responding IVF patients undergoing PPOS and antagonist cycles. STUDY DESIGN, SIZE, DURATION: A clinical translational research study was conducted with IVF patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: This study included 55 normal responding IVF patients who underwent ovarian stimulation with either PPOS using MPA (5 mg twice daily) or GnRH antagonist cetrorelix acetate. Recombinant forms of FSH and hCG were used for ovarian stimulation and ovulation triggering, respectively. Luteinized mural GCs obtained during the oocyte retrieval procedure were used for the experiments. Cell culture, quantitative real-time PCR, immunoblotting, confocal time-lapse live cell imaging, and hormone assays were used. MAIN RESULTS AND THE ROLE OF CHANCE: Demographic and IVF cycle characteristics of the patients undergoing ovarian stimulation with PPOS and GnRH antagonist were similar, including ovarian response, mature oocyte yield, and fertilization rates. Molecular analyses revealed that the expression of the enzymes involved in sex-steroid synthesis (StAR, SCC, 3β-HSD, 17β-HSD, aromatase) and the uptake/storage/utilization of cholesterol (LDL receptor, Hormone-sensitive lipase, hydroxy-methyl glutaryl Co-enzyme-A reductase, and Sterol O-acyltransferase1) in the GCs of the PPOS cycles were comparable to those of the antagonist cycles. The expression of the receptors for gonadotropins, estrogen, and progesterone hormones was also similar. Basal and hCG-induced increases in 3β-HSD expression and progesterone production and basal and FSH-induced increases in aromatase expression and E2 output of the GCs from PPOS patients did not exhibit any meaningful differences when compared with GCs from antagonist cycles. Furthermore, basal and hCG-induced up-regulation in the LDL receptor expression and cholesterol uptake did not differ between the groups. Confocal imaging also revealed similar patterns of expression for the steroidogenic enzymes and their co-localization with mitochondria. Lastly, the expression of the other important genes regulating cumulus expansion, ovulation, and luteal function [Relaxin, ADAMTS-1, and epidermal growth factor (EGF)-like growth factor amphiregulin] in the GCs of the PPOS and antagonist cycles were similar. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Caution should be exercised when interpreting our data which was derived from normally responding patients whose ovulation was triggered with hCG. It is unclear whether the molecular parameters assessed vary according to infertility etiologies, magnitude of ovarian response, mode of trigger, and any other underlying ovarian pathologies or systemic diseases. MPA was the progestin used for PPOS and whether these findings can be generalized to other progestins is unknown. WIDER IMPLICATIONS OF THE FINDINGS: This study provides reassuring molecular evidence that exposure of antral follicle cohorts to MPA during the follicular growth phase does not have any detrimental effects on steroidogenic, ovulatory, and luteal functions when compared with GnRH antagonist cycles. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the School of Medicine, the Graduate School of Health Sciences of Koc University and Koç University Research Center for Translational Medicine (KUTTAM), and equally funded by the Republic of Turkey Ministry of Development Research Infrastructure Support Program. All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.


  • Open Access

    Patients with gynecological malignancies are similar to other IVF patients without cancer for clinical and molecular reproductive parameters and DNA damage response pattern

    by Yashar Esmaeilian, Sevgi Yusufoglu, Ece İlTumur, Deniz Ugurlu Cimen, Dogan Vatansever, Cagatay Taskiran, Volkan Turan, Kayhan Yakin, Said İnCir, Bulent Urman, et al.

    This study intended to investigate if gynecological cancers compromise ovarian function and reduce the success of assisted reproduction techniques (ART). No clinical and molecular data together is available on this issue for gynecological or other organ cancers. Steroidogenic pathways and DNA damage response characteristics of the granulosa cells retrieved from the 39 gynecological cancer patients were analyzed together with their clinical ART characteristics in comparison to 31 control ART patients. Patients with gynecological malignancies were similar to the control IVF patients for the number of mature oocytes retrieved, fertilization rates and embryo development competency. Molecular analyses of the granulosa cells retrieved from these cancer patients did not detect any perturbations in gonadotropin receptor expression and response, sex steroid production, cholesterol utilization/storage and, DNA damage response pattern in comparison to control IVF patients without cancer. This study provides the first reassuring clinical and molecular combined data set that the presence of gynecological malignancy does not appear to have any detrimental effect on clinical IVF cycle characteristics and ovarian functioning at molecular level.


  • Visualizing Lipophagy as a New Mechanism of the Synthesis of Sex Steroids in Human Ovary and Testis Using Immunofluorescence Staining Method

    by Yashar Esmaeilian, Sevgi Yusufoglu, Ece Iltumur, Gamze Bildik, Ozgur Oktem

    Immunofluorescence, a transformative tool in cellular biology, is employed to dissect the intricate mechanisms of cholesterol trafficking in human reproductive tissues. Autophagy, a key player in cellular homeostasis, particularly lipophagy, emerges as a free cholesterol source for steroidogenesis. In this chapter, we describe a comprehensive immunofluorescence staining protocol, with details provided for the precise visualization of subcellular dynamics of mitochondria, lysosomes, and lipid droplets in ex vivo testicular tissue and primary luteal granulosa cell culture models, pivotal components in sex steroid biosynthesis. Here, we detail the culture, treatment, and immunofluorescence protocols, providing a comprehensive guide for researchers. The provided immunofluorescence toolkit serves as a valuable resource for researchers, paving way for advancements in human reproductive health to investigate the intricate interplay between autophagy, lipophagy, and cholesterol trafficking. Key words Autophagy Confocal microscopy ImageJ Immunofluorescence staining Luteinized granulosa cells Steroidogenesis Testis


  • Real-Time Visualization of Cholesterol Trafficking in Human Granulosa Cells Using Confocal Live Cell Microscopy as a Tool to Study the Novel Role of Autophagy in Sex Steroid Synthesis

    by Yashar Esmaeilian, Ozgur Oktem

    Autophagy is an evolutionarily conserved process that aims to maintain the energy homeostasis of the cell by recycling long-lived proteins and organelles. We have very recently demonstrated that lipophagy, a special form of autophagy, mediates the association of the lipid droplets (LDs) with lysosomes to deliver the lipid cargo within the LDs to lysosomes for degradation in order to release free cholesterol required for steroid synthesis in human ovary and testis. In this chapter, we describe live cell confocal microscopy technique that allows us to monitor real-time cholesterol trafficking and the association of cholesterol-laden LDs with lysosome (lipophagy) in human granulosa cells. Key words Autophagy Cholesterol Lipid droplet Luteinized granulosa cell Live cell imaging Confocal microscopy ImageJ